Form 4: Sangamo Therapeutics Insider Option Grant

Nikunj Jain, Principal Accounting Officer at Sangamo Therapeutics, received a stock option grant for 225,000 shares.

Summary

• Nikunj Jain, identified as the Principal Accounting Officer of Sangamo Therapeutics, Inc., was granted a stock option on April 1, 2026.
• The option provides the right to purchase 225,000 shares of common stock at an exercise price of $0.2601 per share.
• The option has an expiration date of March 31, 2036.
• Vesting of the option occurs in stages: one-quarter vests on the first anniversary of the grant date, with the remaining shares vesting in 24 equal monthly installments thereafter.
• Vesting is contingent upon Jain's continued service with the company and is subject to acceleration provisions outlined in the 2018 Employee Incentive Plan (EIP).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider stock option grant with a defined vesting schedule, providing no immediate indication of significant positive or negative company performance.

Positives

• Grant of stock options to a key officer, Nikunj Jain, aligns incentives with company performance.
• The option grant provides a long-term incentive with an expiration date of March 31, 2036.
• A structured vesting schedule encourages continued service and commitment to the company.

Negatives

• The exercise price of $0.2601 per share is very low, which could indicate a historical low stock price or a significant discount.
• The filing does not provide context on the rationale for the specific exercise price or the number of options granted.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Sangamo Therapeutics.
• Vesting is subject to continued employment, meaning any departure before full vesting would result in forfeiture of unvested options.
• The option grant is subject to acceleration provisions, the details of which are not fully disclosed in this filing.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation, as the vesting and exercise are tied to continued service and market value.

Management Comments

• "One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."

Industry Context

StockSavvy.ai notes that grants of stock options to key executives are a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize talent, especially given the high-risk, high-reward nature of drug development.

Stakeholder Impact

• Shareholders: The grant of options to management is a standard practice and does not immediately impact shareholders, but it represents potential future dilution if exercised. The low exercise price may be a point of discussion regarding executive compensation.
• Employees: The vesting schedule for Nikunj Jain aligns his incentives with continued service, potentially benefiting employee morale if the company performs well.
• Management: Nikunj Jain receives a long-term incentive tied to the company's success.

Next Steps

• Nikunj Jain will continue to provide services to Sangamo Therapeutics, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• The options may be exercised by Nikunj Jain upon vesting, subject to market conditions and company policy.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Stock Option, Insider Trading, Beneficial Ownership, Nikunj Jain, Principal Accounting Officer, Vesting Schedule, SEC Filing